Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 9% After Earnings Miss

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded down 9% during trading on Thursday following a dissappointing earnings announcement. The stock traded as low as $16.41 and last traded at $17.2570. 1,315,844 shares were traded during mid-day trading, a decline of 50% from the average session volume of 2,631,512 shares. The stock had previously closed at $18.97.

The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 49.42%. The business had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. During the same period in the previous year, the firm earned $1.90 EPS. The company’s revenue was down 32.7% compared to the same quarter last year.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue topped Street estimates, showing better-than-expected top-line performance for the quarter despite product-specific weakness. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Management emphasized a solid balance sheet and cash position on the call/press release, which can support R&D and the transition period. Press Release: Q4 and Full-Year 2025 Financial Results
• Positive Sentiment: New longer-term and safety data will be presented at the MDA Clinical & Scientific Congress, offering potential catalysts if data are favorable. MDA Conference Presentation Announcement
• Neutral Sentiment: Full earnings materials and the call transcript/slides are available for investors to review management’s details on costs, cash burn and product strategies. Earnings Slides / Press Release
• Negative Sentiment: Earnings per share missed badly: SRPT reported a loss of $3.58/share vs. consensus around a $0.87 loss, a large downside surprise that pressured the stock. MarketBeat Q4 Summary
• Negative Sentiment: Elevidys sales “tumbled,” driving much of the revenue decline vs. prior year and signaling market-share and demand challenges for Sarepta’s key product. Zacks: Sales Beat but Elevidys Sales Tumble
• Negative Sentiment: Revenue declined ~33% year-over-year, underscoring that the company is in a down cycle and must show steady recovery to restore investor confidence. Yahoo Finance: Compared to Estimates
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon replacement), creating near-term leadership uncertainty during a critical turnaround period. Reuters: CEO to Retire
• Negative Sentiment: Company issued cautious 2026 guidance, signaling recovery will be gradual — investors typically punish biotech names that lower near-term visibility into growth. Yahoo Finance: Guidance and Recovery Path

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of recent analyst reports. Wells Fargo & Company reduced their target price on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and an average price target of $33.84.

Insider Transactions at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently modified their holdings of the company. Yousif Capital Management LLC lifted its position in Sarepta Therapeutics by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after buying an additional 481 shares during the last quarter. State of Michigan Retirement System grew its position in Sarepta Therapeutics by 3.1% during the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 700 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Sarepta Therapeutics by 2.8% during the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 717 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Sarepta Therapeutics by 6.1% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 728 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after purchasing an additional 744 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

The company has a market cap of $1.83 billion, a P/E ratio of -2.07, a price-to-earnings-growth ratio of 0.48 and a beta of 0.39. The company’s fifty day moving average is $20.51 and its 200 day moving average is $20.22. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.